{"id":670669,"date":"2023-10-03T18:56:01","date_gmt":"2023-10-03T18:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=670669"},"modified":"2023-10-03T18:56:01","modified_gmt":"2023-10-03T18:56:01","slug":"her2positive-breast-cancer-market-size-in-the-us-was-approximately-usd-1600-million-in-2022-estimates-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/her2positive-breast-cancer-market-size-in-the-us-was-approximately-usd-1600-million-in-2022-estimates-delveinsight_670669.html","title":{"rendered":"HER2-Positive Breast Cancer Market Size in the US was approximately USD 1,600 Million in 2022, Estimates DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1696323752.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"HER2-Positive Breast Cancer Market Size in the US was approximately USD 1,600 Million in 2022, Estimates DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1696323752.png\" alt=\"HER2-Positive Breast Cancer Market Size in the US was approximately USD 1,600 Million in 2022, Estimates DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">&ldquo;The HER2-Positive Breast Cancer market is expected to surge due to the disease&rsquo;s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- HER2-Positive Breast Cancer pipeline products will significantly revolutionize the HER2-Positive Breast Cancer market dynamics&rdquo;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The HER2-Positive Breast Cancer market report provides current treatment practices, HER2-Positive Breast Cancer emerging drugs, market share of individual therapies, and current and forecasted 7MM a HER2-Positive Breast Cancer market size from 2019 to 2032. The report also covers current HER2-Positive Breast Cancer treatment market practices\/algorithms and unmet medical needs to curate the best opportunities and assess the market&rsquo;s underlying potential<strong>.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the HER2-Positive Breast Cancer Market Research Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In 2022, the United States accounted for the maximum share of the total market of HER2-positive breast cancer in the 7MM was around 60%.<\/li>\n<li>The approval of HERCEPTIN marked a turning point in HER2+ breast cancer treatment. HERCEPTIN was the first targeted treatment for a solid tumor and the first drug to be paired with a companion diagnostic.<\/li>\n<li>The leading companies working in the HER2-Positive Breast Cancer Market include Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, iOMEDICO AG, Seagen Inc., Iqvia Pty Ltd, Daiichi Sankyo Inc., Merck Sharp &amp; Dohme LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others.<\/li>\n<li>Promising HER2-Positive Breast Cancer Pipeline Therapies in the various stages of development include TUKYSA&reg;, Trastuzumab deruxtecan, Tucatinib, Trastuzumab, Pertuzumab, and others.<\/li>\n<li>September 2023: Baptist Health South Florida announced a study of phase 1 clinical trials for Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine. This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab.<\/li>\n<li>September 2023: H. Lee Moffitt Cancer Center and Research Institute announced a study of phase 1 clinical trials for Trastuzumab and Pepinemab. The purpose of this study is to test the safety of Adoptive T-Cell therapy following the Dendritic Cell (DC1) study vaccine given in combination with pepinemab added to standard of care therapy, trastuzumab to help people with HER2 positive breast cancer.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major HER2-Positive Breast Cancer Market Share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/her2-positive-breast-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">HER2-Positive Breast Cancer Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>HER2-Positive Breast Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Breast cancer initiates when abnormal cancerous cells in the breast grow and proliferate, creating a tumor. It usually starts in the ducts or lobules of the breast. Some breast cancers depend on the human epidermal growth factor receptor 2 (HER2) gene to grow. These cancers are called HER2+ and have many copies of the HER2 gene or high levels of the HER2 protein. These proteins are also called &ldquo;receptors.&rdquo;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>HER2-Positive Breast Cancer Epidemiology Segmentation in the 7MM<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total HER2-Positive Breast Cancer Incident cases<\/li>\n<li>HER2-Positive Breast Cancer Hormonal status<\/li>\n<li>HER2-Positive Breast Cancer Age-specific cases<\/li>\n<li>HER2-Positive Breast Cancer Stage-specific cases<\/li>\n<li>HER2-Positive Breast Cancer Line wise metastatic cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving HER2-Positive Breast Cancer Epidemiology Trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/her2-positive-breast-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">HER2-Positive Breast Cancer Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>HER2-Positive Breast Cancer Marketed Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>ENHERTU (fam-trastuzumab deruxtecan-nxk): Daiichi Sankyo\/AstraZeneca<\/li>\n<li>KADCYLA (ado-trastuzumab emtansine): Roche\/Chugai<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>HER2-Positive Breast Cancer Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>ARX788: Ambrx<\/li>\n<li>Zanidatamab: Zymeworks\/Jazz Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about HER2-Positive Breast Cancer Treatment options, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/her2-positive-breast-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">HER2-Positive Breast Cancer Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>HER2-positive Breast Cancer Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">Numerous treatment options for HER2-positive breast cancer are available, falling into pharmacological and nonpharmacological categories. Recent advancements in HER2 treatments have enhanced HER2-positive breast cancer management, yet relapse remains a primary challenge due to disease heterogeneity and drug resistance mechanisms. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. Roche responded actively to the rise of biosimilars by introducing a subcutaneous (SC) formulation of HERCEPTIN in the EU in 2013 and the US in 2019, despite the availability of biosimilars.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>HER2-Positive Breast Cancer Therapeutics Market <\/strong><\/p>\n<p style=\"text-align: justify;\">Herceptin has been the foundation of traditional HER2+ cancer treatment. It targets HER2 receptors, which may keep the cancer from growing. The Genentech Oncology Co-pay Assistance Program helps people with commercial health insurance. The Genentech Patient Foundation gives free Herceptin to people who do not have insurance coverage or who have financial concerns. If a patient needs help with the Genentech medicine co-pay, Herceptin Access Solutions can refer the patient to an independent co-pay assistance foundation. Independent co-pay assistance foundations help patients with public or commercial health insurance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the HER2-Positive Breast Cancer Pipeline Therapies in clinical trials @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/her2-positive-breast-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">HER2-Positive Breast Cancer Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the HER2-Positive Breast Cancer Market Research Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- 7MM<\/li>\n<li>Study Period- 2019-2032<\/li>\n<li>HER2-Positive Breast Cancer Companies- Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, iOMEDICO AG, Seagen Inc., Iqvia Pty Ltd, Daiichi Sankyo Inc., Merck Sharp &amp; Dohme LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others.<\/li>\n<li>HER2-Positive Breast Cancer Pipeline Therapies- TUKYSA&reg;, Trastuzumab deruxtecan, Tucatinib, Trastuzumab, Pertuzumab, and others.<\/li>\n<li>HER2-Positive Breast Cancer Market Dynamics: HER2-Positive Breast Cancer Market Drivers and Barriers<\/li>\n<li>HER2-Positive Breast Cancer Market Access and Reimbursement, Unmet Needs, and Future Perspectives<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about HER2-Positive Breast Cancer Drugs in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/her2-positive-breast-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">HER2-Positive Breast Cancer Ongoing Clinical Trials Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. HER2-positive Breast Cancer Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4. Executive Summary of HER2-positive Breast Cancer<\/p>\n<p style=\"text-align: justify;\">5. Key Events<\/p>\n<p style=\"text-align: justify;\">6. Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">7. Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">8. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">9. Patient Journey<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints in HER2-positive Breast Cancer<\/p>\n<p style=\"text-align: justify;\">11. Marketed Drugs<\/p>\n<p style=\"text-align: justify;\">12. Emerging Drugs<\/p>\n<p style=\"text-align: justify;\">13. HER2-positive Breast Cancer: 7MM Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. HER2-positive Breast Cancer Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">15. Unmet needs<\/p>\n<p style=\"text-align: justify;\">16. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Appendix<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=her2positive-breast-cancer-market-size-in-the-us-was-approximately-usd-1600-million-in-2022-estimates-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/ci-tracking\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/ci-tracking<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/ci-tracking\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=her2positive-breast-cancer-market-size-in-the-us-was-approximately-usd-1600-million-in-2022-estimates-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&ldquo;The HER2-Positive Breast Cancer market is expected to surge due to the disease&rsquo;s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- HER2-Positive Breast Cancer pipeline products will significantly revolutionize the HER2-Positive Breast Cancer market dynamics&rdquo; &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/her2positive-breast-cancer-market-size-in-the-us-was-approximately-usd-1600-million-in-2022-estimates-delveinsight_670669.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-670669","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/670669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=670669"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/670669\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=670669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=670669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=670669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}